The objective of this proposal is to establish a Pediatric Component of the Adult ACTU in Western N.Y. Through State funding as a N.Y.S. Department of Health AIDS Institute, AIDS Designated Center in Rochester and as a SUNY Health Science Center in Syracuse, Pediatric Clinics have been established to provide care to HIV-infected children and infants exposed at birth as parts of comprehensive HIV programs. The Pediatric HIV Clinics are physically distinct from, but closely integrated with, Adult and Maternal HIV programs. The Pediatric Component of the Adult ACTU will be completely integrated with existing Pediatric HIV Clinics using the same staff to provide protocol and non-protocol care. Participation in ACTG protocols will afford otherwise unattainable therapeutic interventions to HIV- infected children in Western N.Y. while contributing Phase I-III data to the NIAID that will help in the development and selection of therapeutic agents for subsequent FDA approval. The Pediatric Component of the Adult ACTU will evaluate the safety and efficacy of therapeutic interventions for infants, children and adolescents with asymptomatic HIV infection, symptomatic HIV infection and conditions and opportunistic infections associated with HIV infection. Well established interactions between the Maternal and Pediatric Components will facilitate enrollment of HIV-infected women into therapeutic protocols that will require follow-up and/or therapy of the infants. Investigators will be involved in protocol development, patient enrollment and follow-up, data analysis and the presentation and publication of results.

Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
1996
Total Cost
Indirect Cost
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Gupta, S K; Kitch, D; Tierney, C et al. (2015) Markers of renal disease and function are associated with systemic inflammation in HIV infection. HIV Med 16:591-8
Vardhanabhuti, Saran; Ribaudo, Heather J; Landovitz, Raphael J et al. (2015) Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia. Open Forum Infect Dis 2:ofv085
Longenecker, Chris T; Kitch, Douglas; Sax, Paul E et al. (2015) Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s. J Acquir Immune Defic Syndr 69:168-77
Moore, Carrie B; Verma, Anurag; Pendergrass, Sarah et al. (2015) Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis 2:ofu113

Showing the most recent 10 out of 153 publications